News for Oxford Immunotec Global Stock (OXFD)

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

PRNewsWire • 03/04/21

Oxford Immunotec (OXFD) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zacks Investment Research • 02/22/21

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Ko

GlobeNewsWire • 02/08/21

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

GlobeNewsWire • 02/04/21

New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19

GlobeNewsWire • 01/14/21

Oxford Immunotec's T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva's VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study

GlobeNewsWire • 01/13/21

Oxford Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Oxford Immunotec Global PLC Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – OXFD

Business Wire • 01/07/21

Why Oxford Immunotec Stock Is Skyrocketing Today

The Motley Fool • 01/07/21

Medical Stock Mashup: PerkinElmer, Oxford Unite In $591 Million Deal

Investors Business Daily • 01/07/21

PerkinElmer to Acquire Oxford Immunotec Global PLC

Business Wire • 01/07/21

Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week

GlobeNewsWire • 12/16/20

Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea

GlobeNewsWire • 12/10/20

Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

GlobeNewsWire • 12/02/20

Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020

GlobeNewsWire • 11/23/20

Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec's T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec

GlobeNewsWire • 11/10/20

Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit

GlobeNewsWire • 11/05/20

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha • 11/03/20

Oxford Immunotec (OXFD) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research • 11/03/20

Oxford Immunotec Reports Third Quarter 2020 Financial Results

GlobeNewsWire • 11/03/20

UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials

GlobeNewsWire • 10/22/20

Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020

GlobeNewsWire • 10/21/20

Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two

GlobeNewsWire • 09/29/20

Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test

GlobeNewsWire • 09/22/20

Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q2 2020 Results - Earnings Call Transcript

Seeking Alpha • 08/09/20

Oxford Immunotec (OXFD) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research • 08/04/20